The emergence of new COVID-19 variants is seen denting the efficacy of vaccines and AstraZeneca is the first to take a hit.
The vaccine developed by the University of Oxford ran into trouble in South Africa on Sunday after it failed to ward off the B.1.351 variant in 95 percent of 1750 healthy an
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
